Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.schres.2014.08.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology.
Front Pharmacol
December 2022
Department of History of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Article Synopsis
- Monoamine oxidases are important enzymes that break down key neurotransmitters like adrenaline, serotonin, and dopamine, helping maintain balance in the brain.
- Numerous drugs, known as monoamine oxidase inhibitors (MAOIs), have been developed to regulate these enzymes for clinical use in treating mental health disorders.
- The paper highlights historical milestones of notable MAOIs, including banisterine, iproniazid, and others, emphasizing their contributions to the development of psychopharmacology, dating back to the 1920s with the use of harmine for schizophrenia symptoms.
Harmine for catatonic schizophrenia. A forgotten experiment.
Schizophr Res
October 2014
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Occurrence and partition of the beta-carboline norharman in rat organs.
Life Sci
July 1993
Section Pathophysiology of Behaviour, Medical Faculty, Erasmus University Rotterdam, The Netherlands.
The beta-carboline norharman was determined in plasma, brain, liver, kidney, spleen, heart and lung of the rat using HPLC with fluorescence detection. In order to improve the speed and sensitivity of this assay an earlier published sample clean-up extraction procedure and HPLC method were adjusted. Norharman was found to be present in plasma as well as in all organs tested, concentrations in organs being about 80 times higher than those in plasma.
View Article and Find Full Text PDFModification of drug-induced catatonia and tremors by quapazine in rats and mice.
Jpn J Pharmacol
April 1980
Administration of perphenazine, tremorine, nicotine and harmine induced Parkinson-like symptoms in rats and mice. The efficacy of quipazine, a serotonin agonist, in antagonizing these drug-induced Parkinsonian symptoms was assessed. Combinations of this drug with other antiparkinsonian agents such as scopolamine, diphenhydramine and amantadine were also studied in the manifestation of Parkinson-like symptoms in the animal models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!